The document provides an analysis of the financial statements of Sun Pharmaceutical Industries Ltd for the years 2017-2022. It summarizes the company's income statement, balance sheet trends, and sales performance. The income statement shows rising sales turnover but fluctuating net profits. The balance sheet analysis indicates overall growth in total assets and liabilities. Current liabilities increased while long-term debt declined on the liability side. On the asset side, current assets grew whereas fixed assets witnessed a fall. Sales performance was positively impacted by the pandemic with highest ever domestic sales in India, though US sales saw a temporary dip.

1. PRESTIGE INSTITUTE OF MANAGEMENT
AND RESEARCH, INDORE
EXTERNAL GROUP PRESENTATION
TOPIC – FINANCIAL STATEMENT ANALYSIS of SUN PHARMA
SUBMITTED BY:
GROUP NO – 8
KAMYA SINGH
KANCHAN PETHIYA
KARAMVEER SINGH
KARAN MEHRA

2. INTRODUCTION
• Being an Indian Multinational Pharmaceuticals Company, Sun Pharma, continue to
remain steadfast in their transformation journey, building additional pathways of
growth and simultaneously focusing on making the organisation more efficient. Their
specialty business is one of the key initiatives in this transformation journey, targeting
an innovation driven business model to drive sustainable and profitable growth. They
have invested significant resources over the past few years in building this business;
and are now focusing on commercial execution to ensure that future cash-flows
justify these investments.
• While the COVID-19 pandemic has resulted in near term uncertainty. Their strategic
initiatives, coupled with their goal strengths, resilience and power of execution, give
them the confidence of navigating this uncertainty and remain focused on their
transformation journey.

3. ABOUT THE COMPANY
• Sun Pharmaceuticals Industries Ltd. Is an Indian multinational Pharmaceuticals company headquartered
in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and active
pharmaceutical ingredients (APIs) primarily in India and the United States.
• Sun Pharmaceuticals was established by Mr. Dilip Shanghvi in 1983in Vapi, Gujarat. Today, it is
the largest chronic prescription company in India and a market leader in psychiatry, neurology,
cardiology, orthopaedics, ophthalmology, gastroenterology & nephrology.
• The 2014 acquisition of Ranbaxy made Sun the largest pharma company in India, the largest
Indian pharma company in the US. Sun pharma was listed on the stock exchange in 1994.
• Today Sun Pharma is the second largest and the most profitable pharmaceutical company in
India, as well as the largest pharmaceutical company by market capitalisation on the Indian
exchanges.

4. Sun Pharmaceuticals Industries
Profit & Loss Account ( in Rs. Cr.)
Mar ‘22 Mar ‘21 Mar ‘20 Mar ‘19 Mar ‘18
12 months 12 months 12 months 12 months 12 months
Income
Sales Turnover 38,654.49 33,498.14 32,837.50 29,065.91 26,489.46
Excise Duty 0.00 0.00 0.00 0.00 73.92
Net Sales 38,654.49 33,498.14 32,837.50 29,065.91 26,415.54
Other Income -3,666.87 -3,475.89 348.14 -188.89 -60.97
Stock Adjustments 107.61 638.22 -300.85 433.11 -230.70
Total Income 35,095.23 30,660.47 32,884.79 29,310.13 26,123.87
Expenditure
Raw Materials 11,257.45 9,982.03 9,552.33 8,302.08 7,945.13
Power & Fuel Cost 702.78 627.09 621.89 0.00 559.97
Employee Cost 7,300.83 6,862.23 6,862.35 5,967.09 5,367.05
Other Manufacturing
Expenses
557.81 0.00 0.00 0.00 0.00
Miscellaneous Expenses 8,545.51 8,173.64

5. RESULTS OF SUN PHARMA
• 21.11.22 - Inflationary pressure on input costs shadows healthy revenue growth in
Quarter 2.
• 01.11.22 – SUN PHARMA Consolidated September 2022 Net Sales at Rs 10,952.28
crore, up 13.78% Y-o-Y
• 01.11.22 – SUN PHARMA Standalone September 2022 Net Sales at Rs 5,285,29
crore, up 27.57% Y-o-Y
• 01.11.22 – SUN PHARMA consolidated net profit rises more than 8%, beats estimate.

6. ANALYSIS OF SUN PHARMA
• 29.05.19 - Global brokerages stay positive on SUN PHARMA, see 14-31% upside after
Quarter 4.
• 13.02.19 - SUN PHARMA Quarter 3 profit jump 4-fold; brokerages see nearly 30%
upside in 12 months.
• 16.08.18 - SUN PHARMA Quarter 1 review: All eyes on the speciality business.
• 16.08.18 – Analysts turn mixed on Sun Pharma despite Quarter 1 nos beat estimates;
CLSA ups target to Rs 750.

7. ANALYSIS OF BALANCE SHEET OF SUN PHARMA
SUN PHARMA Balance Sheet as on March 2018
No. of Months Year Ending 12 March 2017 12 March 2018 % Change
Net worth Rs (Cr.) 366,370 383,141 4.6
Current Liabilities Rs (Cr.) 178,870 198,643 11.1
Long-term Debt Rs (Cr.) 14,361 17,721 23.4
Total Liabilities Rs (Cr.) 589,174 621,090 5.4
Current Assets Rs (Cr.) 329,537 316,359 -4.0
Fixed Assets Rs (Cr.) 259,638 304,731 17.4
Total Assets Rs (Cr.) 589,174 621,090 5.4

8. SUN PHARMA Balance Sheet Analysis
• The company’s current liabilities during FY18 stood at Rs 199 billion as compared to Rs 179 billion in
FY17, thereby witnessing an increase of 11.1%.
• Long- term debt stood at Rs 18 billion as compared to Rs 14 billion during FY17, a growth of 23.4%.
• Current assets fell 4% and stood at Rs 316 billion, while fixed assets rose 17% and stood at Rs 305
billion in FY18.
• Overall, the total assets and liabilities for FY18 stood at Rs 621 billion as against Rs 589 billion during
Fy17, thereby witnessing a growth of 5%.

9. SUN PHARMA Balance Sheet as on March 2019
No. of Months Year Ending 12 March 2018 12 March 2019 % Change
Net worth Rs (Cr.) 383,141 414,091 8.1
Current Liabilities Rs (Cr.) 198,643 173,396 -12.7
Long-term Debt Rs (Cr.) 17,721 15,226 -14.1
Total Liabilities Rs (Cr.) 621,090 621,389 0.0
Current Assets Rs (Cr.) 316,359 310,692 -1.8
Fixed Assets Rs (Cr.) 304,731 310,698 2.0
Total Assets Rs (Cr.) 621,090 621,389 0.0

10. SUN PHARMA Balance Sheet Analysis
• The company’s current liabilities during FY19 down at Rs 173 billion as compared to Rs 199 billion in
FY18, thereby witnessing an decrease of -12.7%.
• Long-term debt down at Rs 15 billion as compared to Rs 18 billion during FY18, a fall of 14.1%.
• Current assets fell 2% and stood at Rs 311 billion, while fixed assets rose 2% and stood at Rs 311 billion
in FY19.
• Overall, the total assets and liabilities for FY19 stood at Rs 621 billion as against Rs 621 billion during
FY18, thereby witnessing a growth of 0%.

11. SUN PHARMA Balance Sheet as on March 2020
No. of Months Year Ending 12 March 2019 12 March 2020 % Change
Net worth Rs (Cr.) 414,091 452,645 9.3
Current Liabilities Rs (Cr.) 173,396 157,064 -9.4
Long-term Debt Rs (Cr.) 15,226 20,289 33.3
Total Liabilities Rs (Cr.) 621,389 650,772 4.7
Current Assets Rs (Cr.) 310,692 316,542 1.9
Fixed Assets Rs (Cr.) 310,698 334,230 7.6
Total Assets Rs (Cr.) 621,389 650,772 4.7

12. SUN PHARMA Balance Sheet Analysis
• The company’s current liabilities during FY20 down at Rs 157 billion as compared to Rs 173 billion in
FY19, thereby witnessing an decrease of -9.4%.
• Long-term debt stood at Rs20 billion as compared to Rs 15 billion during FY19, a growth of 33.3%.
• Current assets rose 2% and stood at Rs 317 billion, while fixed assets rose 8% and stood at Rs 334 billion
in FY20.
• Overall, the total assets and liabilities for FY20 stood at Rs 651 billion as against Rs 621 billion during
FY19, thereby witnessing a growth of 5%.

13. SUN PHARMA Balance Sheet as on March 2021
No. of Months Year Ending 12 March 2020 12 March 2021 % Change
Net worth Rs (Cr.) 452,645 464,628 2.6
Current Liabilities Rs (Cr.) 157,064 161,456 2.8
Long-term Debt Rs (Cr.) 20,289 8,981 -55.7
Total Liabilities Rs (Cr.) 650,772 641,103 -1.5
Current Assets Rs (Cr.) 316,542 304,421 -3.8
Fixed Assets Rs (Cr.) 334,230 336,628 0.7
Total Assets Rs (Cr.) 650,772 641,103 -1.5

14. SUN PHARMA Balance Sheet Analysis
• The company’s current liabilities during FY20 stood at Rs 161 billion as compared to Rs 157 billion in
FY20, thereby witnessing an increase of 2.8%.
• Long-term debt down at Rs 9 billion as compared to Rs 20 billion during FY20, a fall of 55.7%.
• Current assets fell 4% and stood at Rs 304 billion, while fixed assets rose 1% and stood at Rs 337 billion
in FY21.
• Overall, the total assets and liabilities for FY21 stood at Rs 641 billion as against Rs 651 billion during
FY20, thereby witnessing a fall of 1%.

15. SUN PHARMA Balance Sheet as on March 2022
No. of Months Year Ending 12 March 2021 12 March 2022 % Change
Net worth Rs (Cr.) 464,628 480,112 3.3
Current Liabilities Rs (Cr.) 161,456 172,006 6.5
Long-term Debt Rs (Cr.) 6,547 2,299 -64.9
Total Liabilities Rs (Cr.) 641,103 669,032 4.4
Current Assets Rs (Cr.) 304,421 350,150 15.0
Fixed Assets Rs (Cr.) 336,628 318,882 -5.3
Total Assets Rs (Cr.) 641,103 669,032 4.4

16. SUN PHARMA Balance Sheet Analysis
• The company’s current liabilities during FY22 stood at Rs 172 billion as compared to Rs 161 billion
in FY21, thereby witnessing an increase of 6.5%.
• Long-term debt down at Rs 2 billion as compared to RS 7 billion during FY21, a fall of 64.9%.
• Current assets rose 15% and stood at Rs 350 billion, while fixed assets fell 5% and stood at Rs 319
billion in FY22.
• Overall, the total assets and liabilities for FY22 stood at Rs 669 billion as against Rs 641 billion
during FY21, thereby witnessing a growth of 4%.

17. 30.264
26.066
28.686
32.325 33.498
38.49
0
5
10
15
20
25
30
35
40
45
2017 2018 2019 2020 2021 2022
SALES (Rs CRORES)
6.964
2.096
2.665
3.764
6.8
8.8
0
2
4
6
8
10
2017 2018 2019 2020 2021 2022
Net Profit(Rs. Crore)
SALES
As per the following the sales initiatives
2022 the sales growth of Sun Pharma
FY22 is at it’s highest level as
compared to previous financial years
which shows the highest ever sales
achieved by the firm in a financial year.
NET PROFIT
After making a best ever sale in India &
Foreign countries Sun Pharma have to
compromise with the low net profit
comparing to the previous FYs. Due to the
COVID-19 affect the cost management got
a bit disturbed as the raw materials and
other resources peaks their price in the
market.

18. 13.517
8.747
10.671 10.543
11.62 12.1
0
2
4
6
8
10
12
14
16
2017 2018 2019 2020 2021 2022
USA Sales ( Rs. Crore)
7.749 8.029
7.348
9.71
10.66
11.32
0
2
4
6
8
10
12
2017 2018 2019 2020 2021 2022
INDIA SALES (Rs,
Crores)
USA SALES
As the COVID-19 struck the world the
transportation and supply chain is
heavily affected which caused in the low
sales in USA for Sun Pharma FY22, but
after the pandemic the sales in USA
again started increasing.
INDIA SALES
As the Pandemic hit the country the
sales in India rises to the highest level
as compared to the previous financial
years. FY22 proved to be the highest
sales in India for Sun Pharma.

19. CONCLUSION
• We come up with a conclusion over the Indian Multinational Company Sun Pharmaceuticals Industries Ltd. is a
public limited company incorporated and domiciled in India, having it’s registered office at Vadodara, Gujarat, India
and is listed on the Bombay Stock Exchange Limited and National Stock Exchange of India Limited.
• The Company is in the business of manufacturing, developing and marketing a wide range of branded and generic
formulations and Active Pharmaceutical Ingredients.
• Being a global pharma leader with 36000+ employees worldwide, 40+ manufacturing sites, and 100+ markets
served, Sun Pharma strongly believed that business and responsibility go hand in hand.
• Long- term growth can only be achieved when they will continuously take care of all the three bottom lines –
economic, environmental and social.
• This responsible approach has been the hallmark of their company since many years, which leads them to become
one of the leading Pharmaceuticals company in the world.

20. Thank you.